AbbVie receives EMA and FDA orphan drug designation for investigational compound ABT-414 in the treatment of Glioblastoma multiforme
4 August 2014 | By AbbVie
AbbVie announced the European Medicines Agency and the U.S. Food and Drug Administration have granted orphan drug designation to AbbVie's investigational compound ABT-414...




















